Neurology
-
ATLANTIS Trial: Alteplase for Ischemic Stroke 3–5 Hours After Symptom Onset
The ATLANTIS trial, published in JAMA in 1999, evaluated whether intravenous recombinant tissue-type plasminogen activator, also known as rt-PA or alteplase, improves outcomes in patients with acute ischemic stroke when given 3 to 5 hours after symptom onset. At the time, thrombolysis had already shown benefit when administered early after ischemic stroke. ATLANTIS asked an…